Cardiovascular
-
Can you lower Lp(a)? The drugs in trials, and why none is approved yet
For years the only advice on a high Lp(a) was to drive every other risk factor down, because nothing touched the number itself. Five drugs are about to change that, and the first real test of whether it matters has not reported yet.
-
Nattokinase bleeding risk: aspirin, blood thinners, and surgery
The same fibrinolytic action that makes nattokinase interesting is what puts people in the emergency room. Two case reports, both fatal-adjacent, show the two ways it goes wrong.
-
Does TRT raise blood pressure? What the FDA label change means
The heart risk on testosterone was not erased, it was made specific. The FDA moved it from a boxed warning nobody could act on to a number you can measure at home for the price of a cuff.
-
ApoB and Lp(a): what a normal cholesterol panel misses
A cholesterol panel can call you fine while the number that actually drives plaque sits unmeasured. Two markers, one of them a single lifetime test, fix that.
-
Nattokinase and arterial plaque: what the evidence supports
A soybean enzyme with one genuinely striking plaque study, a modest blood pressure effect, and a bleeding risk nobody mentions. What holds up and what does not.